Abstract
Ibuprofen is a chiral nonsteroidal anti-inflammatory drug (NSAID) of the 2 arylpropionic acid (2-APA) class. A common structural feature of 2-APA NSAIDs is a sp 3-hybridised tetrahedral chiral carbon atom within the propionic acid side chain moiety with the S-(+)-enantiomer possessing most of the beneficial anti-inflammatory activity. Ibuprofen demonstrates marked stereoselectivity in its pharmacokinetics. Substantial unidirectional inversion of the R-(−) to the S-(+) enantiomer occurs and thus, data generated using nonstereospecific assays may not be extrapolated to explain the disposition of the individual enantiomers.
The absorption of ibuprofen is rapid and complete when given orally. The area under the plasma concentration-time curve (AUC) of ibuprofen is dose-dependent. Ibuprofen binds extensively, in a concentration-dependent manner, to plasma albumin. At doses greater than 600mg there is an increase in the unbound fraction of the drug, leading to an increased clearance of ibuprofen and a reduced AUC of the total drug. Substantial concentrations of ibuprofen are attained in synovial fluid, which is a proposed site of action for nonsteroidal anti-inflammatory drugs.
Ibuprofen is eliminated following biotransformation to glucuronide conjugate metabolites that are excreted in urine, with little of the drug being eliminated unchanged. The excretion of conjugates may be tied to renal function and the accumulation of conjugates occurs in end-stage renal disease. Hepatic disease and cystic fibrosis can alter the disposition kinetics of ibuprofen. Ibuprofen is not excreted in substantial concentrations into breast milk.
Significant drug interactions have been demonstrated for aspirin (acetylsalicylic acid), cholestyramine and methotrexate. A relationship between ibuprofen plasma concentrations and analgesic and antipyretic effects has been elucidated.
Similar content being viewed by others
References
Adams SS, Cliffe EE, Lessel B, et al. Some biological properties of 2-(4-isobutylphenyl)propionic acid [short report]. J Pharm Sci. 1967; 56: 1686.
Adams SS, Bresloff P, Mason CG. Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (−)-isomer. J Pharm Pharmacol. 1976; 28: 256–7.
Geisslinger G, Stock KP, Bach GL, et al. Pharmacological differences between R(−)- and S(+)-ibuprofen. Agents Actions. 1989; 27: 455–7.
Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 1992; 42: 237–56.
Villaneuva M, Heckenberger R, Strobach H, et al. Equipotent inhibition by R(−)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. Br J Clin Pharmacol. 1993; 35: 235–42.
Evans AM, Nation RL, Sansom LN, et al. Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane synthesis and the plasma unbound concentration of S(+)-ibuprofen. Br J Clin Pharmacol. 1991; 31: 131–8.
Busson M. Update on ibuprofen: review article. J Int Med Res. 1986; 14: 53–62.
Davies EF, Avery GS. Ibuprofen: a review of its pharmacological properties and therapeutic efficacy in rheumatic disorders. Drugs. 1971; 2: 416–46.
Verbeeck RK. Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs. J Rheumatol 1988; 17 Suppl.: 44–57.
Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet. 1995; 28: 100–14.
Davies NM. Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. Clin Pharmacokinet. 1996; 31: 331–47.
Brocks DR, Jamali F. Etodolac clinical pharmacokinetics. Clin Pharmacokinet. 1994; 26: 259–74.
Brocks DR, Jamali F. Clinical Pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet. 1992; 23: 415–27.
Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet. 1990; 19: 197–217.
Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997; 32: 268–93.
Kaiser DG, Vangiessen GJ. GLC determination of ibuprofen [(±)-2-(p-isobutylphenyl)propionic acid in plasma. J Pharm Sci. 1974; 63: 219–21.
Fujise H. A simple and sensitive colorimetric determination of ibuprofen from plasma and urine in dogs after dosing. Jpn J Vet Sci. 1977; 39: 671–3.
Hoffman DJ. Rapid GLC determination of ibuprofen in serum. J Pharm Sci. 1977; 66: 749–50.
Midha KK, Cooper JK, Hubbard JW, et al. A rapid and simple GLC procedure for determinations of plasma concentrations of ibuprofen. Can J Pharm Sci. 1977; 12: 29–31.
Hackett LP, Dusci LJ. Gas-liquid Chromatographic determination of ibuprofen in human plasma. Clin Chim Acta. 1978; 87: 301–3.
Kaiser DG, Martin RS. Electron-capture GLC determination of ibuprofen in serum. J Pharm Sci. 1978; 67: 627–30.
Singh NN, Pasutto FM, Coutts RT, et al. Gas Chromatographic separation of optically active anti-inflammatory 2-arylpropionic acids using (+)- or (−)-amphetamine as derivatizing reagent. J Chromatogr. 1986; 378: 125–35.
Dusci LJ, Hackett LP. Determination of some anti-inflammatory drugs in serum by high-performance liquid chromatography. J Chromatogr. 1979; 172: 516–9.
Pitrè D, Grandi M. Rapid determination of ibuprofen in plasma by high-performance liquid chromatography. J Chromatogr. 1979; 170: 278–81.
Runci FM, Segre G. Gas Chromatographic determination of ibuprofen in plasma and in biological fluids. Chromatogr Symp Ser. 1979; 1: 199–201.
Orzalesi G, Mari F, Bertol E, et al. Anti-inflammatory agents: determination of ibuproxam and its metabolite in humans. Arzneimittel Forschung. 1980; 30: 1607–9.
Ali A, Kazmi S, Plakogiannis FM. High-pressure liquid Chromatographic determination of ibuprofen in plasma. J Pharm Sci. 1981; 70: 944–5.
Kearns GL, Wilson JT. Determination of ibuprofen in serum by high-performance liquid chromatography and application to ibuprofen disposition. J Chromatogr. 1981; 226: 183–90.
Shimek JL, Rao NGS, Khalil SK. High-pressure liquid Chromatographie determination of ibuprofen in plasma. J Pharm Sci. 1981; 70: 514–6.
Snider BG, Beaubien LJ, Sears DJ, et al. Determination of flurbiprofen and ibuprofen in dog serum with automated sample preparation. J Pharm Sci. 1981; 70: 1347–9.
Lockwood GF, Wagner JG. High-performance liquid Chromatographie determination of ibuprofen and its major metabolites in biological fluids. J Chromatogr. 1982; 232: 335–43.
Aarons L, Grennan DM, Siddiqui M. The binding of ibuprofen to plasma proteins. Eur J Clin Pharmacol. 1983; 25: 815–8.
Ford B, Vine J, Watson TR. A rapid extraction method for acidic drugs in hemolyzed blood. J Anal Toxicol. 1983; 7: 116–8.
Hirai T, Matsumoto S, Kishi I. Simultaneous analysis of several non-steroidal anti-inflammatory drugs in urine by high-performance liquid chromatography with normal-phase extraction. J Chromatogr B 1997; 375–88.
Greenblatt DJ, Arendt RM, Locniskar A. Ibuprofen pharmacokinetics: use of liquid chromatography with radial compression separation. Arzneimittel Forschung. 1983; 33: 1671–3.
Senekjian HO, Leee CS, Kuo TH, et al. Absorption and disposition of ibuprofen in hemodialyzed uremic patients. Eur J Rheumatol Inflamm. 1983; 6: 155–62.
Heikkinen L. Quantitative determination of ibuprofen by glass capillary gas chromatography using three different methylation methods. Acta Pharm Fenn. 1983; 92: 275–82.
Albert KS, Raabe A, Garry M, et al. Determination of ibuprofen in capillary and venous plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Sci. 1984; 73: 1487–9.
Aravind MK, Miceli JN, Kauffman RE. Determination of ibuprofen by high-performance liquid chromatography. J Chormatogr. 1984; 308: 350–3.
Heikkinen L. Silica caplillary gas Chromatographic determination of ibuprofen in serum. J Chromatogr. 1984; 307: 206–9.
Litowitz H, Olanoff L, Hoppel CL. Determination of ibuprofen in human plasma by high-performance liquid chromatography. J Chromatogr. 1984; 311: 443–8.
Chan EM, Chan SC. Screening for acidic and neutral drugs by high performance liquid chromatography in post-mortem blood. J Anal Toxicol. 1984; 8: 173–6.
Ginman R, Karnes HT, Perrin J. Simultaneous determination of codeine and ibuprofen by high-performance liquid chromatography. J Pharm Biomed Anal. 1985; 3: 439–45.
Jonkman HG, Schoenmaker R, Holtkamp AH, et al. Determination of ibuprofen in human plasma by solid phase extraction and reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal. 1985; 3: 433–8.
Giachetti C, Canali S, Zanolo G. Separation of non-steroidal anti-inflammatory agents by high-resolution gas chromatography. Preliminary trials to perform pharmacokinetic studies. J Chromatogr. 1983; 279: 587–92.
Levine B, Caplan YH. Simultaneous liquid-chromatographic determination of five nonsteroidal anti-inflammatory drugs in plasma or blood. Clin Chem. 1985; 31: 346–47.
Shah A, Jung D. Improved high-performance liquid Chromatographie assay of ibuprofen in plasma. J Chormatogr. 1985; 344: 408–11.
Lee EJD, Williams KM, Graham GG, et al. Liquid Chromatographie determination and plasma concentration profile of optical isomers of ibuprofen in humans. J Pharm Sci. 1984; 73: 1542–4.
Averginos A, Hutt AJ. High-performance liquid Chromatographie determination of ibuprofen in human plasma and urine by direct injection. J Chromatogr. 1986; 380: 468–71.
LaLande M, Wilson DL, MCGilveray IJ. Rapid high-performance liquid Chromatographic determination of ibuprofen in human plasma. J Chromatogr. 1986; 377: 410–4.
Omile CI, Tebett IR. Determination of ten anti-inflammatory drugs in serum by isocratic liquid chromatography. Chromatographia. 1986; 22: 1–6.
Young MA, Aarons L, Davidson EM, et al. Stereospecific assay of ibuprofen and its metabolites [abstract]. J Pharm Pharmacol. 1986; 38: 60.
Kaluzny BD, Bannow CA. High-performance liquid Chromatographie determination of pimeprofen and its metabolite ibuprofen in sheep plasma and lymph. J Chromatogr. 1987; 414: 228–34.
Moore CM, Tebbett IR. Rapid extraction of anti-inflammatory drugs in whole blood for HPLC analysis. Forsenic Sci Int. 1987; 34: 155–8.
Owen SG, Roberts MS, Freisen WT. Rapid high-performance liquid Chromatographic assay for the simultaneous analysis of non-steroidal anti-inflammatory drugs in plasma. J Chromatogr. 1987; 416: 293–302.
Chai B, Minkler PE, Hoppel CI. Determination of ibuprofen and its major metabolites in human urine by high-performance liquid chromatography. J Chromatogr. 1988; 430: 93–101.
Karnes HT, Rajasekharaiah K, Small RE, et al. Automated solid phase extraction and HPLC analysis of ibuprofen in plasma. J Liq Chromatogr. 1988; 11: 489–9.
Berner G, Engels B, Vogtle-Junkert U. Percutaneous ibuprofen therapy with trauma-dolgit gel: bioequivalence studies. Drugs Expt Clin Res. 1989; 15: 559–64.
Lapique F, Netter P, Bannwarth B, et al. Identification and simultantaneous determination of non-steroidal anti-inflammatory drugs using high-performance liquid chromatography. J Chromatogr. 1989; 496: 301–20.
Satterwhite JH, Boudinot FD. High-performance liquid Chromatographic determination of ibuprofen in rat and human plasma. J Chromatogr. 1989; 497: 330–5.
Schulz M, Schmoldt A. Determination of nonsteroidal anti-inflammatory drugs in human plasma by high-performance liquid chromatography. Pharm Ztg Wiss. 1989; 134: 41–4.
Streete PJ. Rapid high-performance liquid Chromatographic methods for the determination of some non-steroidal anti-inflammatory drugs in plasma or serum. J Chromatogr. 1989; 495: 179–93.
Berner G, Staab R, Wagener HH. Determination of ibuprofen in plasma, synovial fluid and tissue by HPLC with electrochemical detection in the lower ng-range. Fresenius J Anal Chem. 1990; 336: 238.
Marzo A, Reiner A, Monti N, et al. Evaluation of ibuprofen dimethylaminoethanol octyl bromide and related active metabolites in biological samples. Arzneimittel Forschung. 1990; 40: 614–7.
Rustum AM. Measurement of ibuprofen in human whole blood by reversed-phase ion-paired high-performance liquid chromatography using a pH-stable polymeric column. J Chromatogr. 1990; 526: 246–53.
Nahata MC. Determination of ibuprofen in human plasma by high-performance liquid chromatography. J Liq Chromatogr. 1991; 14: 187–92.
Rustum AM. Assay of ibuprofen in human plasma by rapid and sensitive reversed-phase high-performance liquid chromaography: application to a single dose pharmacokinetic study. J Chromatogr Sci. 1991; 29: 16–20.
Yamashita K, Motohashi M, Yashiki T. Column-switching techniques for high-performance liquid chromatography of ibuprofen and mefenamic acid in human serum with short-wavelength ultraviolet detection. J Chromatogr. 1991; 570: 329–38.
Blagbrough IS, Daykin MM, Doherty M, et al. PN. High-performance liquid Chromatographic determination of diclofenac, ibuprofen and diclofenac in plasma and synovial fluid in man. J Chromatogr. 1992; 578: 251–7.
Jack DS, Rumble RH, Davies NW, et al. Enantiospecific gas chromatographic-mass spectrometric procedure for the determination of ketoprofen and ibuprofen in synovial fluid and plasma: application to protein binding studies. J Chromatogr. 1992; 584: 189–97.
Jung ES, Lee HS, Rho JK et al. Simultaneous determination of ibuproxam and ibuprofen in human plasma by HPLC with column switching. Chromatographia. 1993; 37: 618–22.
Zhao M-J, Peter C, Holtz M-C, et al. Gas chromatographic-mass spectrometric determination of ibuprofen enantiomers in human plasma using R(−)-2,2,2-trifluoro-1-(9-anthryl)ethanol as derivatizing reagent. J Chromatogr. 1994; 656: 441–6.
Steijger OM, Lingeman H, Brinkman UAT, et al. Liquid Chromatographic analysis of carboxylic acids uszng N-(4-aminobutyl)-N-ethylisoluminol as chemiluminescent label: determination of ibuprofen in saliva. J Chromatogr. 1993; 615: 97–110.
Kim K-R, Shim W-H, Shin Y-J, et al. Capillary gas chromatography of acidic non-steroidal antiinflammatory drugs as tertbutyldimethylsilyl derivatives. J Chromatogr. 1993; 641: 319–27.
Rifai N, Sakamoto M, Law T, et al. Use of a rapid HPLC assay for determination of pharmacokinetic parameters of ibuprofen in patients with cystic fibrosis. Clin Chem. 1994; 42: 1812–6.
Wilson WH. Direct enantiomeric resolution of ibuprofen and flurbiprofen by packed column SFC. Chirality. 1994; 6: 216–9.
Kim K-R, Shin Y-J, Shim W-H, et al. Rapid gas Chromatographie profiling and screening of acidic non-steroidal anti-inflammatory drugs in biological samples. Arch Pharm Res. 1994; 17: 175–81.
Vangiessen GJ, Kaiser DG. GLC determination of ibuprofen [dl-2-(p-isobutylphenyl)propionic acid] enantiomers in biological specimens. J Pharm Sci. 1975; 64: 798–801.
Crowther JB, Covey TR, Dewey EA, et al. Liquid chromatographic/mass spectrometric determination of optically active drugs. Anal Chem. 1984; 56: 2921–6.
Giachetti C, Zanolo G, Canali S. Topical administration of ibuprofen in man: simultaneous determination of the drug and its metabolites in urine by high resolution gas chromatography. J High Res Chromatogr Commun. 1985; 8: 465–8.
Whitlam JB, Vine JH. Quantitation of ibuprofen in biological fluids by gas chromatography-mass spectrometry. J Chromatogr. 1980; 181: 463–8.
Averginos A, Hutt AJ. Determination of the enantiomeric composition of ibuprofen in human plasma by high-performance liquid chromatography. J Chromatogr. 1987; 415: 75–83.
Minkler PE, Hoppel CL. Determination of ibuprofen in human plasma by high-perfomance liquid chromatography. J Chromatogr. 1988; 428: 388–94.
Nicoll-Griffith DA, Inaba T, Tang BK, et al. Method to determine the enantiomers of ibuprofen from humna urine by high-performance liquid chromatography. J Chromatogr. 1988; 428: 103–12.
Mehvar R, Jamali F, Pasutto FM. Liquid-chromatographic assay of ibuprofen enantiomers in plasma. Clin Chem. 1988; 34: 493–6.
Geisslinger G, Dietzel K. High-performance liquid Chromatographie determination of ibuprofen, its metabolites and enantiomers in biological fluids. J Chromatogr. 1989; 491: 139–49.
Martin W, Koselowske G, Toberich H, et al. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm Drug Disp. 1990; 11: 265–78.
Menzel-Soglowek S, Geisslinger G, Brune K. Stereoselective high-performance liquidchromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral α1-acid glycoprotein column. J Chromatogr. 1990; 532: 295–303.
Pettersson K-J, Olsson A. Liquid Chromatographic determination of the enantiomers of ibuprofen in plasma using a chiral AGP column. J Chromatogr. 1991; 563: 414–8.
Theis DL, Halstead GW, Halm KA. Development of capillary gas chromaotgraphic-mass spectrometric methodology for the simultaneous determination of ibuprofen and [ar-2H4] ibuprofen in serum: demonstration of kinetic equivalence in the beagle. J Chromatogr. 1986; 380: 77–87.
Wright MR, Sattari S, Brocks DR, et al. Improved high-performance liquid Chromatographic assay method for the enantiomers of ibuprofen. J Chromatogr. 1992; 583: 259–65.
Lemko CH, Caillé G, Foster RT. Stereospecific high-performance liquid Chromatographic assay of ibuprofen: improved sensitivity and sample processing efficiency. J Chromatogr. 1993; 619: 330–5.
Ahn H-Y, Shiu GK, Trafton WF, et al. Resolution of the enantiomers of ibuprofen; comparison study of diastereomeric method and chiral stationary phase method. J Chromatogr B. 1994; 653: 163–9.
De Vries JX, Schmitz-Kummer E, Siemon D. The analysis of ibuprofen enantiomers in human plasma and urine by high-performance liquid chromatography on an α1-acid glycoprotein chiral stationary phase. J Liq Chromatogr. 1994; 17: 2127–45.
Kondo J, Suzuki N, Naganuma H, et al. Enantiospecific determination of ibuprofen in rat plasma using chiral fluorescence derivatization reagent, (−)-2-[4-(1-aminoethyl)-phenyl]-6-methoxybenzoxazole. Biomed Chromatogr. 1994; 8: 170–4.
Naidong W, Lee JW. Development and validation of a liquid Chromatographic method for the qunatitation of ibuprofen enantiomers in human plasma. J Pharm Biomed Anal. 1994; 12: 551–6.
Kunsman GW, Rohrig TP. Tissue distribution of ibuprofen in a fatal overdose. Am J Forensic Med Pathol. 1993; 14: 48–50.
Péhourcq F, Lagrange F, Labat L, et al. Simultaneous measurement of flurbiprofen, ibuprofen, and ketoprofen enantiomer concentrations in plasma using L-leucinamide as the chiral coupling component. J Liq Chromatorgr. 1995; 18: 3969–79.
Gabard B, Nirnberger G, Schiel H, et al. Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen. Eur J Clin Pharmacol. 1995; 48: 505–11.
Lau YY. Determination of ibuprofen enantiomers in human plasma by derivatization and high performance liquid chromatography with fluoresence detection. J Liq Chromatogr Rel Technol. 1996; 19: 2143–53.
Terfloth GJ, Pirkle WH, Lynam KG, et al. Broadly applicable polysiloxane-based chiral stationary phase for high-performance liquid chromatography and supercritical fluid chromatography. J Chromatogr. 1995; 705: 185–94.
Suzuki N, Naganuma H, Kondo J, et al. Enantiospecific determination of ibuprofen in rat plasma using chiral fluorescence derivatization reagent, (−)-2-[4-(1-Aminoethyl)phenyl]-6-methoxybenzoxazole [abstract]. Int Symp Mol Chir. 1994; 524: 314.
Askholt J, Nielsen-Kudsk F. Rapid HPLC-Determination of ibuprofen and flurbiprofen in plasma for therapeutic drug control and pharmacokinetic applications. Acta Pharmacol Toxicol. 1986; 59: 282–6.
Sochor J, Klimes J, Zahradnicke M, et al. High-Performance liquid chromaotgraphic assay for ibuprofen in whole blood using soli-phase extraction. J Chromatogr. 1994; 654: 282–6.
Brooks CJW, Gilbert MT. Studies of urinary metabolites of 2-(4-isobutylphenyl)propionic acid by gas-liquid chromatography-mass spectrometry. J Chromatogr. 1974; 99: 541–51.
Maurer HH, Kraemer T, Weber A. Toxicological detection of ibuprofen and its metabolites in urine using gas chromatography-mass spectrometry (GC-MS). Pharmazie. 1994; 49: 148–50.
Save TK, Parmar DV, Devarajan PV. High-performance thinlayer Chromatographic determination of ibuprofen in plasma. J Chromatogr. 1997; 690: 315–9.
Davies NM. Methods of analysis of chiral non-steroidal anti-inflammatory drugs. J Chromatogr B. 1997; 691: 229–62.
D’Hulst A, Verbeke N. Chiral separation by capillary electrophoresis with oligosaccharides. J Chromatogr. 1992; 608: 275–87.
Maboundou CW, Paintaud G, Berard M, et al. Separation of fifteen non-steroidal anti-inflammatory drugs using micellar electrokinetic capillary chromatography. J Chromatogr B. 1994; 657: 173–83.
Petersson P, Markides KE. Chiral separations performed by supercritical fluid chromatography. J Chromatogr. 1994; 666: 381–94.
Shihabi ZK, Hinsdale ME. Analysis of ibuprofen in serum by capillary electrophoresis. J Chromatogr. 1996; 683: 115–8.
Bhushan R, Parshad V. Resolution of (±)-ibuprofen using L-arginine-impregnated thin-layer chromatography. J Chromatogr. 1996; 721: 369–72.
Toyo’oka T, Ishibashi M, Terao T. Resolution of carboxylic acid enantiomers by high-performance liquid chromaogrpahy with peroxylate chemiluminescence. J Chromatogr. 1997; 627: 75–86.
Mills RFN, Adams SS, Cliffe EE, et al. The metabolism of ibuprofen. Xenobiotica. 1973; 9: 589–98.
Collier PS, D’Arcy PF, Harron DWG, et al. Pharmacokinetic modelling of ibuprofen. Br J Clin Pharmacol. 1978; 5: 528–30.
Mäkelä A-L, Lempiäinen M, Yrjänä T. Ibuprofen in the treatment of juvenile rheumatoid arthritis: metabolism and concentrations in synovial fluid. Br J Clin Pract. 1980; 6: 23–7.
Mäkelä A-L, Lempiäinen M, Ylijoki H. Ibuprofen levels in serum and synovial fluid. Scand J Rheumatol. 1981; 39: 15–7.
Barillari G, Iorio E, Catanese B, et al. A study of the absorption and tolerance of ibuprofen guaiacol ester in man after repeated oral administration. Boll Chim Farm. 1982; 121: 626–31.
Catanese B, Barillari G, Iorio E, et al. Studies on the oral absorption of ibuprofen guaiacol-ester in man. Boll Chim Farm. 1982; 121: 567–72.
Gillespie WR, DiSanto AR, Monovich RE, et al. Relative bioavailability of commercially available ibuprofen oral dosage forms in humans. J Pharm Sci. 1982; 71: 1034–8.
Zanola G, Mondino A, Giachetti G, et al. Humankinetische Untersuchungen mit ibuprofen. Therapiewoche. 1982; 32: 4353–7.
Aarons L, Greenan DM, Rajapakse C, et al. Anti-inflammatory (ibuprofen) drug therapy in rheumatoid arthritis: rate of response and lack of time dependency of plasma pharmacokinetics. Br J Clin Pharmac. 1983; 15: 387–8.
Juhl RP, Van Thiel DH, Dittert LW, et al. Ibuprofen and sulindac kinetics in alcoholic liver disease. Clin Pharmacol Ther. 1983; 34: 104–9.
Lockwood GF, Albert KS, Gillespie WR, et al. Pharmacokinetics of ibuprofen in man. 1: free and total area/dose relationships. Clin Pharmacol Ther. 1983; 31: 97–103.
Stead JA, Freeman M, John EG, et al. Ibuprofen tablets: dissolution and bioavailability studies. Int J Pharm. 1983; 14: 59–72.
Wright CE, Antal EJ, Gillespie WR, et al. Ibuprofen and acetaminophen kinetics when taken concurrently. Clin Pharmacol Ther. 1983; 34(5): 707–10.
Zanola G, Mondino A, Giachetti G, et al. Ibuprofen-serumkonzentration nach oraler applikation von Dolgit® retard. Therapiewoche. 1983; 33: 2114–6.
Albert KS, Gillespie WR, Wagner JG, et al. Effects of age on the clinical pharmacokinetics of ibuprofen. Am J Med. 1984; 6: 47–50.
Pugh MC, Small RE, Garnett WR, et al. Effect of sucralfate on ibuprofen absorption in normal volunteers. Clin Pharm. 1984; 3: 630–3.
Greenblatt DJ, Abernathy DR, Methis R, et al. Absorption and disposition of ibuprofen in the elderly. Arthritis Rheum. 1984; 27: 1066–9.
Abernathy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. Arthritis Rheum. 1985; 28: 1117–21.
Gambaro V, Caligara M, Benvenuti C, et al. Pharmacokinetics of ibuprofen microincapsulated granules. II Farmaco. 1985; 40: 407–15.
Ochs HR, Greenblatt DJ, Matlis R, et al. Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. Clin Pharmacol Ther. 1985; 38: 648–51.
Palva ES, Konno K, Venbo VMK. Bioavailability of ibuprofen from three preparations marketed in Finland. Acta Pharm Fenn. 1985; 94: 31–5.
Anaya AL, Mayersohn M, Conrad KA, et al. The influence of sucralfate on ibuprofen absorption in healthy adult males. Biopharm Drug Disp. 1986; 7: 433–51.
Antal EJ, Wright CE, Brown BL, et al. The influence of hemodialysis on the pharmacokinetics of ibuprofen and its major metabolites. J Clin Pharmacol. 1986; 26: 184–90.
Benvenuti C, Cancellieri V, Gambaro V, et al. Pharmacokinetics of two new oral formulations of ibuprofen. In J Clin Pharmacol Toxicol. 1986; 24: 308–12.
Gallo JM, Gall EP, Gillespie WR, et al. Ibuprofen kinetics in plasma and synovial fluid arthritic patients. J Clin Pharmacol. 1986; 26: 65–70.
Müller FO, Hundt HK, Van Dyk M, et al. Ibuprofen bioavailability: a comparison of brufen and inza. S Afr Med J. 1986; 70: 197–9.
Regazzi BM, Rondanelli R, Ciaroelli L, et al. Evaluation of the absorption from three formulations. Int Clin Pharm Res. 1986; 6: 469–73.
Gontarz N, Small RE, Comstock TJ, et al. Effect of antacid suspension on the pharmacokinetics of ibuprofen. Clin Pharm. 1987; 6: 413–6.
Lau L-B, Feing-Fei M, Xi-De T. Studies on the bioavailability of ibuprofen tablets. Acta Pharm Sin. 1987; 22: 769–76.
Parr AF, Beihn RM, Franz RM, et al. Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of 171Er-labeled sustained-release tablets. Pharm Res. 1987; 4: 486–9.
Berardi RR, Dressman JB, Elta GH, et al. Elevation of gastric pH with ranitidine does not affect the release characterisitcs of sustained release ibuprofen tablets. Biopharm Drug Disp. 1988; 9: 337–47.
Forsyth DR, Jayasinghe KSA, Roberts CJC. Do nizatidine and cimetidine interact with ibuprofen? Eur J Clin Pharmacol. 1988; 35: 85–8.
Källström E, Heikinheimo M, Quiding H. Bioavailability of three commericial preparations of ibuprofen 600mg. J Int Med Res. 1988; 16: 44–9.
Small RE, Johnson SM, Willis HE. Pharmacokinetic and taste evaluation of ibuprofen (Motrin®) 800mg tablets in extemporaneous solution. J Rheumatol. 1988; 15: 345–7.
Stephenson DW, Small RE, Wood JH, et al. Effect of rantitidine and cimetidine on ibuprofen pharmacokinetics. Clin Pharm. 1988; 7: 317–21.
Eller MG, Wright C, Della-Coletta AA. Absorption kinetics of rectally and orally administered ibuprofen. Biopharm Drug Disp. 1989; 10: 269–78.
Sprekeler R, Baurecht W. Pharmakokinetische kennwerte unter therapie mit einem nichtsteroidalen antirheumatikum mit kurzer halbwertszeit bei patienten über 65 jahren. Arzneimittel Forschung. 1989; 39: 912–4.
Wilson CG, Washington N, Greaves JL, et al. Bimodal release of ibuprofen in a sustained-release formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake. Int J Pharm. 1989; 50: 155–61.
Borin MT, Khare S, Beihn RM, et al. The effect of food on gastrointestinal (GI) transit of sustained-release ibuprofen tablets as evaluated by gamma scintigraphy. Pharm Res. 1990; 7: 304–7.
Freidman H, Lanza F, Perry K, et al. Clinical pharmacology of predisintegrated ibuprofen 800mg tablets: an endoscopic and pharmacokinetic study. J Clin Pharmacol. 1990; 30: 57–63.
Hannula AM, Marvola M, Rajamaeki M, et al. Effects of pH regulators used as additives on the bioavailability of ibuprofen from hard gelatin capsules. Acta Pharm Fenn. 1990; 7: 221–7.
Karttunen P, Saano V, Paronen P, et al. Pharmacokinetics of ibuprofen in man: a single-dose comparison of two over-the-counter, 200mg preparations. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 251–5.
Kendall MJ, Jubb R, Bird HA, et al. A pharmacokinetic comparison of ibuprofen sustained-release tablets given to young and elderly patients. J Clin Pharm Ther. 1990; 15: 35–40.
Lenhard G, Kieferndorf U, Berner G, et al. Pharmacokinetik un bioäquivalenz von zwei ibuprofen-formulierungen. Arzneimittel Forschung. 1990; 40: 1358–62.
Konstan MW, Hoppel CL, Chai B-L, et al. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr. 1991; 118: 956–64.
Nahata MC, Durrell DE, Powell DA, et al. Pharmacokinetics of ibuprofen in febrile children. Eur J Clin Pharmacol. 1991; 40: 427–8.
Neuvonen PJ. The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac. Br J Clin Pharmacol. 1991; 31: 263–6.
Saano V, Paronen P, Peura P, et al. Relative pharmacokinetics of three oral 400mg ibuprofen dosage forms in healthy volunteers. In J Clin Pharm Ther Toxicol. 1991; 29: 381–5.
Salas-Herrera IG, Pearson RM, Turner P. Concentration of ibuprofen in cervical mucus. J Pharm Pharmacol. 1991; 43: 142–4.
Small RE, Wilmot-Pater MG, McGee BA, et al. Effects of misoprostol or ranitidine on ibuprofen pharmacokinetics. Clin Pharm. 1991; 10: 870–2.
Brown RD, Wilson JT, Kearns GL, et al. Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. J Clin Pharmacol. 1992; 32: 231–41.
Ceppi Monti N, Gazzaniga A, Gianesello V, et al. Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. Arzneimittel Forschung. 1992; 42: 556–9.
Chen M-L. An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm Res. 1992; 9: 1380–5.
Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr. 1992; 121: 969–73.
Kelley MT, Walson PD, Edge JH, et al. Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. Clin Pharmacol Ther. 1992; 52: 181–9.
Luckow V, Krammer R, Traub R. Vergleichende bioverfugbarkeitsuntersuchung zweier versciedener ibuprofen-granulate. Arzneimittel Forschung. 1992; 42: 1339–42.
Ragni MV, Miller BJ, Whalen R, et al. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HTV(+) hemophilie men. Am J Hem. 1992; 40: 176–82.
Cone JB, Wallace BH, Olsen KM, et al. The pharmacokinetics of ibuprofen after burn injury. J Burn Care Rehabil. 1993; 14: 666–9.
Seth PL. Percutaneous absorption of ibuprofen from different fromulations: comparative study with gel, hydrophilic ointment and emulsion cream. Arzneimittel Forschung. 1993; 43: 919–21.
Al-Meshal MA, El-Sayed YM, Al-Balla SR, et al. The effect of colestipol and cholestyramine on ibuprofen bioavailability in man. Biopharm Drug Disp. 1994; 15: 463–71.
Kaltenbach ML, Mohammed SS, Mullersman G, et al. Pharmacokinetic evaluation of two ibuprofen-codeine combinations. Int J Clin Pharmacol Ther. 1994; 32: 210–4.
Rey E, Pariente-Khayat A, Gouyet L, et al. Stereoselective dispostition of ibuprofen enantiomers in infants. Br J Clin Pharmac. 1994; 38: 373–5.
El-Sayed YM, Gouda MW, Al-Khamis Kl, et al. Comparative bioavailability of two tablet formulations of ibuprofen. Int J Clin Pharmacol Ther. 1995; 33: 294–8.
Kleinbloesem CH, Owerkerk M, Spitznagel W, et al. Pharmacokinetics and bioavailability of percutaneous ibuprofen. Arzneimittel Forschung. 1995; 45: 1117–21.
Walter K, Weib G, Laicher A, et al. Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric-coated microcapsules. Arzneimittel Foschung. 1995; 45: 886–90.
Ntawukulilyayo JD, Veraet C, Remon JP, et al. In vitro and in vivo evaluation of a xanthan gum-n-octenylsuccinate starch matrix tablet containing ibuprofen as a model drug. Int J Pharm. 1996; 139: 79–85.
Pargal A, Kelkar MG, Nayak PJ. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. Biopharm Drug Disp. 1996; 17: 511–9.
Wagener HH, Vögtle-Junkert U. Zur auswertung von wirkstoffkonzentration in geweben nach perkutaner anwendung von nicht-steroidalen antirheumatika. Arzneimittel Forschung. 1996; 46: 299–301.
Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 1997; 86: 289–93.
Jones K, Seymour RA, Hawkesford JE. Are the pharmacokinetics of ibuprofen important determinants for the dru’s efficacy in postoperative pain after third molar surgery? Br J Oral Maxillofac Surg. 1997; 35(3): 173–6.
Lee EJD, Williams KM, Day RO, et al. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol. 1985; 19: 669–74.
Cox SR, Brown MA, Squires DJ, et al. Comparative human study of ibuprofen enantiomer plasma concentrations produced by two commercially available ibuprofen tablets. Biopharm Drug Disp. 1988; 9: 539–49.
Day RO, Williams KM, Graham GG, et al. Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clin Pharmacol Ther. 1988; 43: 480–7.
Jamali F, Singh NN, Pasutto FM, et al. Pharmacokinetics of ibuprofen enantiomers in man following oral administration of tablets with different absorption rates. Pharm Res. 1988; 5: 40–3.
Evans AM, Nation RL, Sansom LN. Lack of effect of cimetidine on the pharmacokinetics of R(−)- and S(+)-ibuprofen. Br J Clin Pharmacol. 1989; 28: 143–9.
Baillie TA, Adams WJ, Kaiser DG, et al. Mechanistic studies of the metabolic chiral inversion of (R)-ibuprofen in humans. J Pharm Exp Ther. 1989; 249: 517–23.
Li G, Treiber G, Klotz U. The ibuprofen-cimetidine interaction stereochemical considerations. Drug Invest. 1989; 1: 11–7.
Averginos A, Hutt AJ. Interindividual variability in the enantiomeric disposition of ibuprofen follwing the oral administration of the racemic drug to healthy volunteers. Chirality. 1990; 2: 249–56.
Evans AM, Nation RI, Sansom LN, et al. The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharm Drug Dispos. 1990; 2: 507–18.
Geisslinger G, Schuster O, Stock KP, et al. Pharmacokinetics of S(+)- and R(−)-ibuprofen in volunteers and first clinical experience of S(+)-ibuprofen in rheumatoid arthritis. Eur J Clin Pharmacol. 1990; 38: 493–7.
Cox SR, Gall EP, Forbes KK, et al. Pharmacokinetics of the R (−) and S(+) enantiomers of ibuprofen in the serum and synovial fluid of arthritic patients. J Clin Pharmacol. 1991; 31: 88–94.
Wagener HH, Kalbhen DA, Berner G, et al. Ibuprofen-racemate und enantiomere. Akt Rheumatol. 1991; 16: 65–9.
Jamali F, Mehvar R, Russell AS, et al. Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. J Pharm Sci. 1992; 81: 221–5.
Levine MAH, Walker SE, Paton TW. The effect of food or sucralfate on the bioavailability of S (+) and R(−) enantiomers of ibuprofen. J Clin Pharmacol. 1992; 32: 1110–4.
Oliary J, Tod M, Nicolas P, et al. Pharmacokinetics of ibuprofen enantiomers after single and repeated doses in man. Biopharm Drug Disp. 1992; 13: 337–44.
Rudy AC, Bradley JD, Ryan SI, et al. Variability in the disposition of ibuprofen enantiomers in osteoarthritic patients. Ther Drug Monitor. 1992; 14: 464–70.
Hall SD, Rudy AC, Knight PM, et al. Lack of presystemic inversion of (R)- to (S)-ibuprofen in humans. Clin Pharmacol Ther. 1993; 53: 393–400.
Geisslinger G, Stock KP, Loew D, et al. Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993; 35: 603–7.
Li G, Treiber G, Maier K, et al. Disposition of ibuprofen in patients with liver cirrhosis: stereochemical considerations. Clin Pharmacokinet. 1993; 25: 154–63.
Walker JS, Knihinicki RD, Seideman P, et al. Pharmacokinetics of ibuprofen enantiomers in plasma and suction blister fluid in healthy volunteers. J Pharm Sci. 1993; 82: 787–90.
Chen C-Y, Chen C-S. Stereoselective disposition of ibuprofen in patients with renal dysfunction. J Pharm Exp Ther. 1994; 258: 590–4.
Smith DE, Paliwal JK, Cox SR, et al. The effect of competitive and non-linear plasma protein binding on the stereoselective disposition and metabolic inversion of ibuprofen in healthy subjects. Biopharm Drug Disp. 1994; 15: 545–61.
Bannwarth B, Lapique F, Pehourq F, et al. Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br J Clin Pharmacol. 1995; 40: 266–9.
Chen C-Y. Influence of age on the stereoselective disposition and metabolism of ibuprofen in humans. J Formos Med Assoc. 1995; 94: 95–100.
Chen C-Y, Chen C-S. Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. Br J Clin Pharmacol. 1995; 40: 67–2.
Knights KM, McLean CF, Tonkin AL, et al. Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R)-ibuprofen in humans. Br J Clin Pharmacol. 1995; 40: 153–6.
Cooper SA, Cowan A, Tallarida RJ, et al. The analgesic interaction of misoprostol with nonsteroidal anti-inflammatory drugs. Am J Ther. 1996; 3: 261–7.
Siemon D, de Vries JX, Stozer F, et al. Fasting and postprandial disposition of R(−) and S(+)-ibuprofen. J Med Res. 1997; 2: 215–9.
Fornasini G, Monti N, Brogin G. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. Chirality. 1997; 9: 297–302.
Hummel T, Cramer O, Mohammadian P, et al. Comparison of the antinociception produced by two oral formulations of ibuprofen: ibuprofeneffervescent vs ibuprofen tablets. Eur J Clin Pharmacol. 1997; 52: 107–14.
Suri A, Grundy BL, Derendorf H. Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. In J Clin Pharmacol Ther. 1997; 35(1): 1–8.
Adams SS, Bough RG, Cliffe EE, et al. Some aspects of the pharmacology, metabolism and toxicology of ibuprofen. Rheumatol Phys Med 1970; Suppl. 9: 9–26.
Wagner JG, Albert KS, Szpunar GJ, et al. Pharmacokinetics of ibuprofen in man IV: absorption and disposition. J Pharmacokinet Biopharm. 1984; 12: 381–99.
Janssen GME, Venema JF. Ibuprofen: plasma concentrations in man. J Int Med Res. 1985; 13: 68–73.
Wagener HH, Vögtle-Junkert U. Intrasubject variability in bioequivalence studies illustrated by the example of ibuprofen. Int J Clin Pharm Ther. 1996; 34: 21–31.
Geisslinger G, Dietzel K, Bezler H, et al. Therapeutically relevant differences in the pharmackinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol. 1989; 27: 324–8.
Adams SS, Warwick Buckler J. Ibuprofen and flurbiprofen. Clin Rheum Dis. 1979; 5: 359–78.
Averginos A, Noormohammadi A, Hutt AJ. Disposition of ibuprofen enantiomers following the oral administration of a novel controlled release formulation to healthy volunteers. Int J Pharm. 1991; 68: 97–103.
Zhao GL, Wang HC. Drug release kinetics of ibuprofen coated granules and their in vitro in vivo correlation. Acta Pharm Sin. 1995; 30: 291–7.
Paliwal JK, Smith DE, Cox SR, et al. Stereoselective, competitive, and nonlinear plasma protein binding of ibuprofen enantiomers as determined in vivo in healthy subjects. J Pharmacokinet Biopharm. 1993; 21: 145–61.
Dominikus M, Nicolakis M, Kotz R, et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittel Forschung. 1996; 46(2): 1138–43.
Mondino A, Zanalo G, Giacheeti C, et al. Humankinetische Untersuchungen mit ibuprofen. Med Welt. 1983; 34: 1052–4.
Kaiser DG, Vangiessen GJ, Reischer RJ, et al. Isomeric inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci. 1976; 2: 269–73.
Wechter WJ, Loughead DG, Reischer RJ, et al. Enzymatic inversion at saturated carbon: nature and mechanism of the inversion of R(−)p-iso-butyl hydratropic acid. Biochem Biophys Res Commun. 1974; 61: 833–7.
Cheng H, Rogers JD, Demetriades JL, et al. Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. Pharm Res. 1994; 11: 824–30.
Cox SR. Effect of route of administration on the chiral inversion of R(−)-ibuprofen [abstract]. Clin Pharmacol Ther. 1988; 21: 146.
Mehvar R, Jamali F. Pharmacokinetic analysis of the enantiomeric inversion of chiral nonsteroidal antiinflammatory drags. Pharm Res. 1988; 5: 76–9.
Romero AJ, Rackley RJ, Rhodes CT. An evaluation of ibuprofen bioinversion by simulation. Chirality. 1991; 3: 418–21.
Rudy AC, Knight PM, Brater DC, et al. Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment. J Pharmacol Exp Ther. 1995; 273: 88–93.
Sawchuk RJ, Rector TS. Drug kinetics in burn patients. Clin Pharmacokinet. 1980; 5: 548–56.
Albert KS, Gernaat CM. Pharmacokinetics of ibuprofen. Am J Med. 1984; 23: 40–6.
Whitlam JB, Brown KR. Ultrafiltration in serum protein binding determinations. J Pharm Sci. 1981; 70: 146–50.
Whitlam JB, Crooks MJ, Brown KF, et al. Binding of non-steroidal anti-inflammatory agents to proteins. I: ibuprofen-serum albumin interaction. Biochem Pharmacol. 1979; 28: 675–8.
Wanwimolrak S, Birkett DJ, Brooks PM. Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet. 1982; 7: 85–92.
Vowles DT, Marchant B. Protein binding of ibuprofen and its relationship to drag interactions. Br J Clin Pract Symp Suppl. 1980; 1: 13–9.
Kober A, Sjöholm I. The binding sites on human serum albumin for some nonsteroidal anti-inflammatory drugs. Mol Pharmacol. 1980; 18: 421–6.
Montero MT, Estelrich J, Vails O. Binding of non-steroidal anti-inflammatory drugs to human serum albumin. Int J Pharm. 1990; 62: 21–5.
Honoré B, Brodersen R. Albumin binding of anti-inflammatory drags: utility of a site-oriented versus a stoichiometric analysis. Mol Pharmacol. 1983; 25: 137–50.
Lockwood GF, Albert KS, Szupunar GJ, et al. Pharmacokinetics of ibuprofen in man — III: plasma protein binding. J Pharm Biopharm. 1983; 11: 469–82.
Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976; 12: 1052–61.
Noctor TAG, Pham CD, Kaliszan R, et al. Stereochemical aspects of benzodiazepine binding to human serum albumin — 1: enantioselective high performance liquid affinity chromaotgraphic examination of chiral and achiral binding interactions between 1,4-benzodiazepines and human serum albumin. J Pharm Exp Ther. 1992; 42: 506–11.
Hage DS, Noctor TAG, Wainer IW. Characterization of the protein binding of chiral drugs by high-performance affinity chromatography interactions of R- and S-ibuprofen with human serum albumin. J Chromatogr. 1995; 693: 23–32.
Hansen T, Day R, Williams K, et al. The assay and in vitro binding of the enantiomers of ibuprofen. Clin Exp Pharmacol Physiol. 1985; 9: 82–3.
Evans AM, Nation RL, Sansom LN, et al. Stereoselective plasma protein binding of ibuprofen enantiomers. Eur J Clin Pharmacol. 1989; 36: 283–90.
Cheravallath VK, Riley CM, Narayanan SR, et al. A quantitative circular dichroic investigation of the binding of the enantiomers of ibuprofen and diclofenac to human serum albumin. J Pharm Biomed Anal. 1997; 15: 1719–24.
Cheravallath VK, Riley CM, Narayanan SR, et al. The effect of octanoic acid on the binding of the enantiomers of ibuprofen and diclofenac to human serum albumin: a Chromatographic implication. Pharm Res. 1996; 13: 173–8.
Glass RC, Swannell AJ. Concentrations of ibuprofen in serum and synovial fluid from patients with arthritis. Br J Clin Pract Sym Suppl. 1978; 6: 453P–54P.
Whitlam JB, Brown KF, Crooks MJ, et al. Transsynovial distribution of ibuprofen in arthritic patients. Clin Pharmacol Ther. 1981; 29: 487–92.
Rau R, Berner G, Wagener HH, et al. Konzentration von ibuprofen und eiwess-gehalt sowie pH-wert in kniegelenkserguss und plasma nach oraler gabe von ibuprofen bei arthritis-patienten. Arzneimittel Forschung. 1989; 39: 1166–8.
Seideman P, Lohrer F, Graham GG, et al. The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid. Br J Clin Pharm. 1994; 38: 221–7.
Fears S. Lipophilic xenobiotic conjugates: the pharmacological and toxicological consequences of the participation of drugs and other foreign compounds as substrates in lipid biosynthesis. Prog Lipid Res. 1985; 24: 177–95.
Williams K, Day R, Knihinicki R, et al. The stereoselective uptake of ibuprofen into adipose tissue. Biochem Pharmacol. 1986; 35: 3403–5.
McGeer Pl, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996; 47(2): 425–32.
Peters H, Chlud K, Berner G et al. Zur perkutanen kinetik von ibuprofen. Akt Rheumatol. 1987; 12: 208–11.
Chlud K, Berner G, Wagener HH. Ibuprofenkonzentrationen in subkutanem fettgewebe, gelenkkapsel und synovialflüssigkeit nach perkutaner anwendung. Therapiewoche. 1985; 35: 2872–6.
Menzel EJ, Kolarz G. Bindungsvermögen von ibuprofen an humanes gewebe. Arzneimittel Forschung. 1992; 42: 325–7.
Menzel EJ, Kolarz G. Bindungsvermogen von ibuprofen an kollagen und andere bindegewebskomponenten. Arzneimittel Forschung. 1990; 40: 481–3.
Steinmetz JC, Lee CY, Wu A-Y. Tissue levels of ibuprofen after fatal overdosage of ibuprofen and acetaminophen. Vet Hum Toxicol. 1987; 29: 381–3.
Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids-a novel route with pharmacological consequences. J Pharm Pharmacol. 1983; 35: 693–704.
Mayer JM. Stereoselective metabolism of anti-inflammatory 2-arylpropionates. Acta Pharm Nord. 1990; 2: 197–216.
Nakamura Y, Yamaguchi T, Takahashi S, et al. Optical isomerization mechanism of R(−)-hydratropic acid derivatives [abstract]. J Pharmacobiodyn. 1981; 4: S–1.
Knihiniicki RD, Day RO, Williams KM. Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drags — I: in vitro studies of ibuprofen and flurbiprofen. Biochem Pharmacol. 1989; 38: 4389–95.
Knihiniicki RD, Day RO, Williams KM. Chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drags — II: racemization and hydrolysis of (R)- and (S)-ibuprofen CoA thioesters. Biochem Pharmacol. 1991; 42: 1905–11.
Brugger R, Aliá BG, Reichel C, et al. Isolation and characterization of rat liver microsomal R-ibuprofenoyl-CoA synthetase. Biochem Pharmacol. 1996; 52: 1007–13.
Chen C-Y, Lu P-H, Chen C-S. Metablic inversion of stereoisomeric ibuprofen in man. J Formos Med Assoc. 1991; 90: 437–42.
Chen C-S, Shieh W-R, Lu P-H, et al. Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochem Biophy Acta. 1991; 1078: 411–7.
Tracy TS, Hall SD. Metabolic inversion of (R)-ibuprofen epimerization and hydrolysis of ibuprofenyl-coenzyme A. Drug Metab Disp. 1991; 20: 322–7.
Tracy TS, Wirthwein DP, Hall SD. Metabolic inversion of (R)-ibuprofen: formation of ibuprofenyl-coenzyme A. Drug Metab Disp. 1992; 21: 114–20.
Menzel S, Waibel R, Brune K, et al. Is the formation of R-ibuprofenyl-adenylate the first stereoslective step of chrial inversion? Biochem Pharmacol. 1994; 48(5): 1056–8.
Rudy AC, Knight PM, Brater DC, et al. Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. J Pharmacol Exp Ther. 1991; 259: 1133–9.
Leeman TD, Tanson C, Bonnabry C, et al. A major role for cytochrome P450tb (CYP2C) subfamily in the actions of non-steroidal anti-inflammatory drugs. Drugs Exp Clin Res. 1993; 19: 189–95.
Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol. 1997; 54: 33–41.
Castillo M, Lam F, Dooley MA, et al. Disposition and covalent binding of ibuprofen and its acylglucuronide in the elderly. Clin Pharmacol Ther. 1995; 57: 636–44.
Spraul M, Hofmann, Dvortsak P, et al. High-performance liquid chromatography coupled to high-field proton nuclear magnetic resonance spectroscopy: application to the urinary metabolites of ibuprofen. Anal Chem. 1993; 65: 327–30.
Wilson ID, Nicholson JK. Solid-phase extraction chromatography and nuclear magnetic resonance spectrometry for the identification and isolation of drug metabolites in urine. Anal Chem 1987; 2830–22.
Spraul M, Hofmann M, Dvortsak P, et al. Liquid chromatography coupled with high-field proton NMR for profiling human urine for endogenous compunds and drug metabolites. J Pharm Biomed Anal. 1992; 10(8): 601–5.
Keep DR, Sidelmann UG, Hansen SH. Isolation and characterization of major phase I and II metabolites of ibuprofen. Pharm Res. 1997; 14(5): 676–80.
Tan SC, Baker JA, Stevens N, et al. Synthesis, Chromatographic resolution and chiroptical properties of carboxyibuprofen stereoisomers: major metabolites of ibuprofen in man. Chirality. 1997; 9: 75–87.
El Mouelhi M, Ruelius HW, Fenselau C, et al. Species-dependent enantioselective glucuronidation of three 2-arylpropionic acids diclofenac, ibuprofen and benoxaprofen. Drug Metab Disp. 1987; 15: 767–72.
Pettersen JE, Ulsaker GA, Jellum E. Studies on the metabolism of 2,4′-isobutylphenylpropionic acid (ibuprofen) by gas chromatography and mass spectrometry. J Chromatogr. 1978; 145: 413–20.
Shirley MA, Guan X, Kaiser DG, et al. Taurine conjugation of ibuprofen in humans and in rat liver in vitro: relationship to metabolic chiral inversion. J Pharm Exp Ther. 1994; 269: 1166–75.
Chen CS, Chen T, Shieh WR. Metabolic stereoisomeric inversion of 2-arylpropionic acids: on the mechanism of ibuprofen epimerization in rats. Biochim Biophys Acta. 1990; 1033(1): 1–6.
Chen CS, Shieh WR, Lu PH. Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochim Biophys Acta. 1991; 1078(3): 411–7.
Schneider HT, Nuernberg B, Dietzel K, et al. Biliary elimination of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol. 1990; 29: 127–31.
Rudy AC, Anliker KS, Hall SD. High-performance liquid Chromatographic determination of the stereochemical metabolites of ibuprofen. J Chromatogr. 1990; 528: 395–405.
Committee on Drugs, American Academy of Pediatrics. Transfer of drugs and other chemicals into human milk. Pediatrics. 1989; 79: 223–8.
Weibert RT, Townsend RJ, Kaiser DG, et al. Lack of ibuprofen secretion into milk. Clin Pharm 1982; 457–8.
Townsend RJ, Benedetti TJ, Erickson SH, et al. Excretion of ibuprofen into breast milk. Am J Obstet Gynecol. 1984; 149: 184–6.
Walter K, Dilger C. Ibuprofen in human milk. Br J Pharmacol. 1997; 44(2): 211–2.
Kimura T, Shirota O, Ohtsu Y. Analysis of ibuprofen metabolites by semi-microcolumn liquid chromatography with ultraviolet absorption and pulsed amperometric detectors. J Pharm Biomed Anal. 1997; 15: 1521–6.
Wechter WJ. Understanding the chiral pharmacology of nonsteroidal antiinflammatory drugs in the aryl propionic acid class. J Clin Pharmacol. 1996; 36 Suppl. 12: 1S–2S.
Evans AM. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol. 1996; 36 Suppl. 12: 7S–15S.
Reichel C, Bang H, Brune K, et al. 2-Arylpropionyl-CoA epimerase: partial peptide sequences and tissue localization. Biochem Pharmacol. 1995; 50: 1803–6.
Meyer JM. Ibuprofen enantiomers and lipid metabolism. J Clin Pharmacol. 1996; 36 Suppl. 12: 27S–32S.
Ahn H-Y, Jamali F, Cox SR, et al. Stereospelective disposition of ibuprofen enantiomers in the isolated perfused rat kidney. Pharm Res. 1991; 8: 1520–4.
Cox PGE, Moons WM, Russel FGM, et al. Renal handling and effects of S(+)-ibuprofen and R(−)-ibuprofen in the rat isolated perfused kidney. Br J Pharmacol. 1991; 103: 1542–6.
Caldwell J, Hutt AJ, Fournel-Gigleux S. The metabolic chiral inversion and disposition enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol. 1988; 37: 105–14.
Knihiniicki RD, Day RO, Graham GG, et al. Stereoselective disposition of ibuprofen and flurbiprofen in rats. Chirality. 1990; 2: 134–40.
Leising G, Resel R, Tash S, et al. Physical aspects of dexibuprofen and racemic ibuprofen. J Clin Pharmacol. 1996; 36 Suppl. 12: 3S–6S.
Dwivedi SK, Mitchell AG, Sattari S, et al. Ibuprofen racemate and enantiomers: phase diagram, solubility and thermodynamic studies. Int J Pharm. 1992; 87: 95–104.
Klein G, Neff H, Kullich W, et al. S(+) versus racemic ibuprofen [letter]. Lancet. 1992; 339: 681.
Chlud K. Evaluation of tolerance and efficacy of S(+)-ibuprofen (Seractil®) in daily practice: a post-marketing-surveillance study in 1400 patients. J Clin Pharmacol. 1995; 35: 921–4.
Stock KP, Geisslinger G, Loew D, et al. S-ibuprofen versus ibuprofen-racemate. Rheumatol Int. 1991; 11: 199–202.
Cullen DJ, Hudson N, Atherton JC, et al. Gastric tolerability of S(+) ibuprofen compared to racemic ibuprofen [abstract]. Gastroenterology. 1995; 108: A78.
Neupert W, Brugger R, Euchenhofer C, et al. Effects of ibuprofen enantiomers and its coenzyme A thioester on human prostaglandin endoperoxide synthases. Br J Pharmacol. 1997; 122: 487–92.
Freneaux E, Fromety B, Berson A, et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids. J Pharm Exp Ther. 1990; 255: 529–35.
Zhao B, Geisslinger G, Hall I, et al. The effect of the enantiomers of ibuprofen and flurbiprofen on the β-oxidation of palmitate in the rat. Chirality. 1992; 4: 137–41.
Reichel C, Brugger R, Bang H, et al. Molecular cloning and expression of a 2-arylpropionyl-coenzyme a epimerase: a key enzyme in the inversion metabolism of ibuprofen. Mol Pharmacol. 1997; 51: 576–82.
Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995; 332: 848–54.
Laska EM, Sunshine A, Marrero I. The correlation between blood levels of ibuprofen and analgesic response. Clin Pharmacol Ther. 1986; 40(1): 1–7.
Greenan DW, Aarons L, Siddiqui M, et al. Dose-response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol. 1983; 15: 311–6.
Grennan DM, Ferry DG, Ashworth ME, et al. The aspirinibuprofen interaction in rheumatoid arthritis. Br J Clin Pharmacol. 1979; 8: 497–503.
Bradley JD, Rudy AC, Katz BP, et al. Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. J Rheumatol. 1992; 19: 130–4.
Malek KW, Velagapudi RB, Harter JG, et al. Pharmacodynamics of ibuprofen (IB) antipyresis in children [abstract]. Clin Pharmacol Ther. 1990; 20: 232.
Garg V, Jusko WJ. Pharmacodynamic modeling of nonsteroidal anti-inflammatory drugs: antipyretic effect of ibuprofen. Clin Pharmacol Ther. 1994; 55: 87–8.
Milsom I, Anderch B. Intra-uterine pressure and serum ibuprofen: observations after oral administration of 400 mg ibuprofen to a patient with primary dysmenorrhoea. Eur J Clin Pharmacol. 1985; 29: 443–6.
Hall AH, Smolinske SC, Conrad FL, et al. Ibuprofen overdose: 126 cases. Ann Emerg Med. 1986; 15: 1308–13.
McElwee NE, Veltri JC, Bradford DC, et al. A prospective, population-based study of acute ibuprofen overdose: complications are rare and routine serum levels are not warranted. Ann Emerg Med. 1990; 19: 657–62.
Jenkinson ML, Fitzpatrick R, Streete PJ, et al. The relationship between plasma ibuprofen concentrations and toxicity in acute ibuprofen overdose. Human Toxicol. 1988; 7: 319–24.
Whelton A, Stout RL, Spilman PS, et al. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med. 1990; 112: 568–76.
Murray MD, Black PK, Kuzmik DD, et al. Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci. 1995; 310: 188–91.
Adamska-Dyniewska, Tkaczewski W, et al. Farmakokinetyka ibuprofenu u chorych z marskoscia watroby. Wiad Lek. 1982; 35: 609–13.
Cooper-Peel C, Brodersen R, Robertston A. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Pharm Toxicol. 1996; 79(6): 297–9.
Grennan DM, Aarons L. Salicylate-NSAID interactions. Ann Rheum Dis 1994; 43: 351–2.
Conrad KA, Mayershohn M, Bliss M. Cimetidine does not alter ibuprofen kinetics after a single dose. Br J Clin Pharmacol. 1984; 18: 624–6.
Small RE, Wood JH. Influence of racial differences on effects of ranitidine and cimetidine on ibuprofen pharmacokinetics. Clin Pharm. 1989; 8: 471–2.
Nicholson PA, Karim A, Smith M. Pharmacokinetics of misoprostol in the elderly, in patients with renal failure and when co-administered with NSAID or antipyrine, propanolol or diazepam. J Rheumatol 1990; 20 Suppl.: S33–7.
Skeith KJ, Russell AS, Jamali F, et al. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol. 1990; 17: 1008–10.
Abdullah ME, El-Sayed YM. Design of crossover microcomputer program and application on drug bioequivalence data. Comput Methods Programs Biomed. 1995; 48: 237–9.
Ragheb M, Ban TA, Buchanan D, et al. Interaction of indomethacin and ibuprofen with lithium in manic patients under a steady-state lithium level. J Clin Psychiatry. 1980; 41: 397–8.
Tracy TS, Krohn K, Jones DR, et al. The effects of a salicylate, ibuprofen, and diclofenac on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992; 42: 121–5.
Quattrocchi FP, Robinson JD, Curry RW, et al. The effects of ibuprofen on serum digoxin concentrations. Drug Intell Clin Pharm. 1983; 17: 286–8.
Goncalves I. Influence of ibuprofen on haemostasis in patients on anticoagulant therapy. J Int Med Res. 1973; 1: 180–5.
Boekhout-Mussert MJ, Loeliger EA. Influence of ibuprofen on oral anti-coagulation with phenprocoumon. J Int Med Res. 1974; 2: 279–83.
Thilo D, Nyman D, Duckert F. A study of the effects of the anti-rheumatic drug ibuprofen (brufen®) on patients being treated with the oral anti-coagulant phenprocoumon (marcoumar®). J Int Med Res. 1974; 2: 276–8.
Duckett F. The absence of effect of antirheumatic drug ibuprofen and oral anticoagulation with phenprocoumon. Curr Med Res Op. 1975; 3: 556–7.
Penner JA, Abbrecht PH. Lack of interaction between ibuprofen and warfarin. Curr Ther Res. 1975; 18: 862–71.
Slattery JT, Levy G. Effect of ibuprofen on protein binding of warfarin in human serum. J Pharm Sci. 1977; 66: 1060.
Schulman S, Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol. 1989; 28: 46–9.
Koopmans PP, Thien TH, Gribnau FWJ. The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. Eur J Clin Pharmacol. 1987; 31: 553–7.
Gurwitz JH, Everitt DE, Monane M, et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly patients. J Gerontol 1996; 51A: M74–M79.
Radack KL, Deck CC. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebocontrolled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987; 107: 628–35.
Wright JT, McKenney JM, Lehaney AM, et al. The effect of high-dose short-term ibuprofen on antihypertensive control with hydrochlorothiazide. Clin Pharmacol Ther. 1989; 46: 440–4.
Minuz P, Lechi A, Arosio E, et al. Antihypertensive activity of enalapril. Effect of ibuprofen and different salt intakes. J Clin Hypertens. 1987; 3: 645–53.
Davies JG, Rawlins DC, Busson M. Effect of ibuprofen on blood pressure control by propranolol and bendrofluazide. J Int Med Res. 1988; 16: 173–81.
Hooten WM, Pearlson G. Delirium caused by tacrine and ibuprofen interaction. Am J Psychiatry. 1996; 153: 842.
Sandyk R. Phenytoin toxcity induced by interaction with ibuprofen. S Afr Med J. 1982; 62: 592.
Bachman KA, Schwartz JI, Forney RB, et al. Inability of ibuprofen to alter single dose phenytoin disposition. Br J Clin Pharmacol. 1986; 21: 165–9.
Lee P, Bell MA, Webb J, et al. A study on the effects of ibuprofen on the metabolism of antipyrine in man. Med J Aust. 1973; 2: 846–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Davies, N.M. Clinical Pharmacokinetics of Ibuprofen. Clin Pharmacokinet 34, 101–154 (1998). https://doi.org/10.2165/00003088-199834020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199834020-00002